Neurizon Therapeutics Limited

DB:ECQ0 Stock Report

Market Cap: €48.2m

Neurizon Therapeutics Past Earnings Performance

Past criteria checks 0/6

Neurizon Therapeutics's earnings have been declining at an average annual rate of -37.6%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 14.5% per year.

Key information

-37.6%

Earnings growth rate

-30.4%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate-14.5%
Return on equity-87.0%
Net Margin-1,057.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Neurizon Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:ECQ0 Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241-934
31 Mar 241-623
31 Dec 234-852
30 Sep 234-751
30 Jun 231-211
31 Mar 232-121
31 Dec 224-131
30 Sep 224-141
30 Jun 225-251
31 Mar 224-241
31 Dec 214-240
30 Sep 214-240
30 Jun 214-141
31 Mar 214-241
31 Dec 203-240
30 Sep 204-241
30 Jun 204-141
31 Mar 204-241
31 Dec 194-251
30 Sep 194-241
30 Jun 194-241
31 Mar 194-141
31 Dec 184-140
30 Sep 184-250
30 Jun 183-350
31 Mar 183-250
31 Dec 173-250
30 Sep 173-240
30 Jun 173-140
31 Mar 173-240
31 Dec 163-331
30 Sep 163-431
30 Jun 163-441
31 Mar 163-341
31 Dec 153-241
30 Sep 153-241
30 Jun 152-231
31 Mar 152-231
31 Dec 142-230
30 Sep 142-230
30 Jun 142-130
31 Dec 132-120

Quality Earnings: ECQ0 is currently unprofitable.

Growing Profit Margin: ECQ0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ECQ0 is unprofitable, and losses have increased over the past 5 years at a rate of 37.6% per year.

Accelerating Growth: Unable to compare ECQ0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ECQ0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).


Return on Equity

High ROE: ECQ0 has a negative Return on Equity (-87.01%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 18:44
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Neurizon Therapeutics Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stefan TanSpark Plus Pte Ltd